Hyperfine Reports Record Preliminary Third Quarter Revenue of Approximately $6.0 Million & Reaffirms Full Year 2026 Revenue Outlook of Approximately $20 to…
Hyperfine, Inc. (HYPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Hyperfine Reports Record Preliminary Third Quarter Revenue of Approximately $6.0 Million & Reaffirms Full Year 2026 Revenue Outlook of Approximately $20 to $22 Million Preliminary Revenue Represents 53% Sequential Quarterly Growth; Company Reaffirms 2026 Financial Gu
How this was made
The 30-second read
Why it matters
The reaffirmed guidance may support the stock and signal continued momentum in the portable MRI market.
Market read
The news is relevant to investors in medical imaging, healthcare technology, and biotech sectors.
What to watch
Potential regulatory hurdles and competition in portable MRI expansion.
Hyperfine Reports Record Preliminary Third Quarter Revenue of Approximately $6.0 Million & Reaffirms Full Year 2026 Revenue Outlook of Approximately $20 to $22 Million
Preliminary third-quarter revenue is expected to reach approximately $6.0 million, up 53% sequentially, while preliminary net cash burn is expected to improve 29% sequentially to approximately $5.6 million. The company reaffirmed its full-year revenue and net cash burn outlook, although the results remain preliminary and unaudited.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Third quarter 2026 preliminary, unaudited revenueother | approximately $6.0 million | 53% sequentially | – |
| Third quarter 2026 preliminary, unaudited net cash burn, excluding financing proceedsnon-GAAP | approximately $5.6 million | 29% sequential improvement | – |
| Nine months ended September 30, 2026 preliminary, unaudited revenueother | approximately $13.8 million | – | 66% |
| Nine months ended September 30, 2026 preliminary, unaudited net cash burn, excluding financing proceedsnon-GAAP | approximately $22.2 million | – | 8% improvement |
| Cash and cash equivalents as of September 30, 2026other | approximately $37.9 million | – | – |
| Cash and cash equivalents as of March 31, 2026other | $40.8M | – | – |
| Cash and cash equivalents as of December 31, 2025other | $35.1M | – | – |
| Net financing proceeds for the quarter ended September 30, 2026other | $0.0 million | – | – |
| Net financing proceeds for the nine months ended September 30, 2026other | approximately $25.0 million | – | – |
| Net financing proceeds for the year ended December 31, 2025other | $27.3M | – | – |
Full year 2026 outlook
- Revenueapproximately $20 to $22 million
- NoteNet cash burn, excluding financing proceeds: approximately $26 to $28 million
- NoteRevenue: 55% growth at the midpoint as compared to full year 2025
- NoteNet cash burn: 10% decline at the midpoint as compared to full year 2025
What drove it
- New and follow-on orders from health systems.
- Expansion across hospital sites of care.
- Adoption in office-based, wellness and longevity, and mobile settings.
- Rollout of the Model 2 Swoop system in international markets.
- Preliminary third-quarter revenue is expected to exceed preliminary third-quarter net cash burn for the first time.
Concerns
- All reported third-quarter and nine-month 2026 financial information is preliminary and unaudited and remains subject to completion of quarter-end closing procedures and further financial review.
- Actual results may differ from the preliminary estimates due to closing procedures, review adjustments and other developments.
- The company expects to provide complete third-quarter 2026 financial results during its earnings call on November 9, 2026.
- The company states that future financing proceeds could cause actual net change in cash and cash equivalents to differ materially from net cash burn guidance.
What to watch
- Final third-quarter 2026 financial results expected during the November 9, 2026 earnings call.
- Whether full-year revenue reaches the reaffirmed approximately $20 to $22 million range.
- Whether full-year net cash burn, excluding financing proceeds, reaches the reaffirmed approximately $26 to $28 million range.
- Progress in health systems, hospital sites of care, office-based, wellness and longevity, mobile, and international settings.
- Cash and cash equivalents following the approximately $37.9 million preliminary September 30, 2026 balance.
Balance sheet and cash flow
- Preliminary, unaudited cash and cash equivalents as of September 30, 2026 are expected to be approximately $37.9 million.
- The Company did not raise any financing proceeds during the third quarter of 2026.
- Cash and cash equivalents were $40.8 million as of March 31, 2026 and $43.5 million as of June 30, 2026.
- Cash and cash equivalents were $37.6 million as of December 31, 2024, $21.6 million as of September 30, 2025, and $35.1 million as of December 31, 2025.
- Net financing proceeds in the aggregate were $10.6 million for the quarter ended June 30, 2026 and $0.0 million for the quarter ended September 30, 2026.
- Net financing proceeds in the aggregate were $8.1 million for the nine months ended September 30, 2025, and preliminary, unaudited are expected to be approximately $25.0 million for the nine months ended September 30, 2026.
- Net financing proceeds in the aggregate were $27.3 million for the year ended December 31, 2025.
Analysis
Hyperfine reported preliminary, unaudited third-quarter revenue expected to be approximately $6.0 million, which it characterized as record revenue and 53% sequential growth. Management attributed commercial momentum to new and follow-on health-system orders, expansion across hospital sites of care, adoption in office-based, wellness and longevity, and mobile settings, plus the Model 2 Swoop rollout in international markets. No revenue by commercial vertical, geography, or product was provided.
Operating leverage was the central accompanying financial message. Preliminary third-quarter net cash burn, excluding financing proceeds, is expected to be approximately $5.6 million, a 29% sequential improvement. The company said preliminary third-quarter revenue is expected to exceed preliminary third-quarter net cash burn for the first time. For the nine months ended September 30, 2026, preliminary revenue is expected to be approximately $13.8 million, up 66%, while preliminary net cash burn is expected to be approximately $22.2 million, an 8% improvement.
Preliminary cash and cash equivalents at September 30, 2026 are expected to be approximately $37.9 million, compared with $43.5 million at June 30, 2026 and $21.6 million at September 30, 2025. The company reported no financing proceeds in the third quarter. However, aggregate net financing proceeds are preliminarily expected to be approximately $25.0 million for the nine months ended September 30, 2026, and the company identifies March 2026 debt financing among the financing sources included in its net cash burn calculation.
Management reaffirmed full-year 2026 revenue guidance of approximately $20 to $22 million and net cash burn, excluding financing proceeds, guidance of approximately $26 to $28 million. The release does not provide gross margin, operating expenses, operating income, net income, EPS, free cash flow, debt, or revenue segment detail. Investors should focus on the final third-quarter results expected on November 9, 2026, because all current-period figures are preliminary, unaudited, and subject to further review.
Management, verbatim
Our preliminary third-quarter results demonstrate that execution of our commercial strategy is driving meaningful growth. Momentum was strong across our three commercial verticals, with new and follow-on orders from health systems, expansion across hospital sites of care, adoption in office-based, wellness and longevity, and mobile settings, and the rollout of our Model 2 Swoop system in international markets.
Maria Sainz, President and Chief Executive Officer of Hyperfine, Inc.
Preliminary expected revenue of approximately $6.0 million represents a significant step up, with 53% sequential growth, while strong operating discipline is reflected in lower cash burn.
Maria Sainz, President and Chief Executive Officer of Hyperfine, Inc.
Not in the filing
stated, not guessed- GAAP gross profit and gross margin
- GAAP operating expenses
- GAAP operating income or loss
- GAAP net income or loss
- GAAP earnings or loss per share
- Non-GAAP earnings or loss per share
- Revenue by segment, product, geography, or commercial vertical
- Prior-year third-quarter revenue
- Prior-quarter revenue amount
- Prior-year third-quarter net cash burn
- Prior-year nine-month revenue amount
- Prior-year nine-month net cash burn amount
- Operating cash flow
- Free cash flow
- Debt balance
- Share repurchases
- Dividends
- Prior outlook for comparison
- Reconciliation of full-year 2026 net cash burn guidance to forward-looking net change in cash and cash equivalents
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Hyperfine filed an 8‑K reporting preliminary Q3 results and reaffirmed its 2026 revenue guidance.
Ticker impact
Hyperfine reaffirmed full-year 2026 revenue outlook of $20‑22M and reported preliminary Q3 revenue of $6M, a 53% sequential increase.
likely modest upside as revenue growth exceeds prior quarter
The new guidance suggests a continued growth trajectory, supporting a bullish outlook for the stock.
Market effects
Highlights growth potential in the portable MRI and medical imaging sector.
Relevant to the US healthcare technology market.
May influence global adoption of portable MRI technology.
Counterpoint
Revenue remains modest; the market may have already priced in growth expectations.
Key entities
- companyHyperfine, Inc.
Medical imaging company reporting preliminary Q3 results.
- executiveMaria Sainz
President and CEO of Hyperfine who commented on the results.
